A Prospective observational, cohort-based, cross-sectional study of Binimetinib in patients with Metastatic Cutaneous and Uveal Melanoma.
Latest Information Update: 02 Dec 2015
Price :
$35 *
At a glance
- Drugs Binimetinib (Primary) ; Sotrastaurin
- Indications Malignant melanoma; Uveal melanoma
- Focus Therapeutic Use
- 02 Dec 2015 New trial record